RxDoctor Payments DataLook up a doctor →

Michelle Murray, NP

Family · Charleston, WVNPI 1194143123

Payments from drug & device makers

$12,815in general payments, 2019–2025

Across 620 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$1K
  • Axsome Therapeutics, Inc.$617
  • plus $5K from 28 others

What the payments were for

  • Food & beverage$12,61498%
  • Education$2012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,815 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$23,547
Medicare patients
279
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter369$336,913
Breztri AerosphereBudesonide/Glycopyr/Formoterol108$92,766
Spiriva RespimatTiotropium Bromide77$67,438
Breo ElliptaFluticasone/Vilanterol89$56,185
SymbicortBudesonide/Formoterol Fumarate116$41,571
Stiolto RespimatTiotropium Br/Olodaterol Hcl52$37,993
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr60$33,187
Albuterol Sulfate HfaAlbuterol Sulfate577$27,556
Incruse ElliptaUmeclidinium Bromide31$20,088
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate81$18,840
Bevespi AerosphereGlycopyrrolate/Formoterol Fum18$10,098
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$8,794
Ventolin HfaAlbuterol Sulfate82$8,183
BreynaBudesonide/Formoterol Fumarate21$5,692
Arnuity ElliptaFluticasone Furoate15$5,671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,549$452,044564 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$2,102$144,435242 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$1,472$105,430129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.

Other family in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →